Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Investing.com -- Shares of Liminatus Pharma Inc (NASDAQ:LIMN) surged 57.3% following the company’s announcement that it has regained compliance with Nasdaq’s listing requirements. The biopharmaceutical firm, which is in the pre-clinical stage of developing immune-modulating cancer therapies, received a notification from Nasdaq on June 3, 2025, confirming its adherence to the Listing Rule 5250(c)(1), which mandates the timely filing of reports with the U.S. Securities and Exchange Commission (SEC).
The positive market response comes after a period of uncertainty for Liminatus. On May 29, 2025, the company was notified by Nasdaq of its non-compliance due to a delay in filing its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. However, the company promptly addressed the issue and filed the required report on June 2, 2025, effectively bringing its Exchange Act reporting obligations up to date.
The resolution of this compliance issue has evidently instilled confidence among investors, as evidenced by the significant uptick in the company’s stock price. The return to compliance means that Liminatus will continue to be listed on the Nasdaq, providing it with continued access to public capital markets, which is essential for funding its ongoing research and development activities.
The swift action taken by Liminatus to rectify the filing delay and the subsequent clearance from Nasdaq underscores the company’s commitment to maintaining good corporate governance practices. Meeting regulatory requirements is critical for biopharmaceutical companies, especially those in the pre-clinical stage, as it helps to foster trust with stakeholders and supports the company’s long-term strategic goals.
As Liminatus moves forward, investors will likely keep a close watch on the company’s progress with its cancer therapy developments, as well as its adherence to financial reporting standards, both of which are pivotal to its growth trajectory and investment appeal.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.